351335-29-0|Methyl 4-((2-formylphenoxy)methyl)benzoate| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 351335-29-0 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 351335-29-0 ]

CAS No. :	351335-29-0
Formula :	C₁₆H₁₄O₄
M.W :	270.28
SMILES Code :	O=C(OC)C1=CC=C(COC2=CC=CC=C2C=O)C=C1
MDL No. :	MFCD01893190
InChI Key :	USZUSRQZXDALNJ-UHFFFAOYSA-N
Pubchem ID :	3455850

Safety of [ 351335-29-0 ]

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H318
Precautionary Statements:	P280-P305+P351+P338+P310

Application In Synthesis of [ 351335-29-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 351335-29-0 ]

[ 351335-29-0 ] Synthesis Path-Downstream 1~19

1
[ 2417-72-3 ]
[ 90-02-8 ]
[ 351335-29-0 ]

Yield	Reaction Conditions	Operation in experiment
100%	With potassium carbonate; sodium iodide; In N,N-dimethyl-formamide; at 80℃; for 0.166667h;Microwave irradiation;	General procedure: A microwave vial was charged with bromomethylbenzene derivative (0.4 mmol, 1 equiv), appropriated phenol derivative (0.44 mmol, 1.1 equiv), K2C03 (0.8 mmol, 2equiv), few crystals of Nal and dimethylformamide (DMF) (1 .4 mL). The reaction mixture was heatedunder microwave irradiation at 80C for 10 minutes. Then, resulted mixture was poured into water and extracted with ethyl acetate. Combined organic phases were washed with brine, dried over Mg504 and concentrated under vacuum. The residue was purified by column chromatography on silica gel (CH2CI2/MeOH)
60%	With potassium carbonate; potassium iodide; In ethyl acetate; at 70℃; for 5.0h;	A suspension of 5, 15 or 28 (6.55mmol) and the corresponding benzaldehydes (6.55mmol) including potassium carbonate (13.10mmol), and potassium iodide (7.86mmol) was heated at 70C for 5h. The solvent was evaporated, the residue was dissolved in ethyl acetate (50mL), washed with saturated aqueous NaHCO3 solution (2×20mL), water (2×20mL), and brine (2×10mL), dried over Na2SO4, and concentrated under reduced pressure. The crude product was purified by flash column chromatography using ethyl acetate/ petroleum ether as an eluent. 4.2.5 Methyl 4-((2-formylphenoxy)methyl)benzoate (6) (white powder, yield 60%) 1H NMR (300MHz, CDCl3): delta 10.57 (s, 1H), 8.07 (d, J=8.43Hz, 2H), 7.86 (d, J=7.50Hz, 1H), 7.53 (d, J=8.43Hz, 2H), 7.76 (t, J=7.50Hz, 1H), 7.06 (t, J=7.50Hz, 1H), 7.01 (d, J=8.44Hz, 1H), 5.25 (s, 2H), 3.92 (s, 3H) ppm. 13C NMR (75.49MHz, CDCl3): delta 189.48, 166.68, 160.64, 141.18, 135.94, 130.03, 128.73, 126.85, 125.19, 121.31, 112.90, 69.76, 52.20ppm. MS (ESI, SQ), m/z (%):293.1 [M+Na]+.

References: [1]Patent: WO2018/50771,2018,A1 .Location in patent: Page/Page column 16; 33.
[2]ACS Medicinal Chemistry Letters,2013,vol. 4,p. 239 - 243.
[3]Bioorganic Chemistry,2019,vol. 92.

2
[ 351335-29-0 ]
[ 1416064-31-7 ]
[ 1335113-30-8 ]

References: [1]ACS Medicinal Chemistry Letters,2013,vol. 4,p. 239 - 243.

3
[ 351335-29-0 ]
[ 1416064-31-7 ]
benzyl 4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)acetyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
56%	With sodium tris(acetoxy)borohydride; In dichloromethane; at 20℃; for 16.0h;	(Methyl 4-((2-((4-(2-(2-((3r,5r,7r)-adamantan-l-yl)acetamido)acetyl)piperazin- l-yl)methyl)phenoxy)methyl)benzoate). A mixture of benzyl 4-(2-(2-((3r,5r,7r)-adamantan-l- yl)acetamido)acetyl)piperazine-l- carboxylate (729 mg, 1.61 mmol) and 10% palladium on carbon (146 mg) in MeOH (10 mL) was stirred for 18 h under hydrogen atmosphere (1 atm). After the palladium catalyst was filtered on celite, the filtrate was concentrated to give crude (l-(adamantan-l-yl)acetamido)acetyl)piperazine (400 mg) as a colorless viscous oil. To a solution of the crude material in CH2C12 (20 mL), 2-(4- methoxycarbonyl)benzyloxybenzaldehyde (406 mg, 1.50 mmol) and sodium triacetoxyborohydride (397 mg, 1.88 mmol) were added. After stirring for 16 h at RT, the mixture was poured into water and extracted with EtOAc. The combined extracts were washed with saturated brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by flash column chromatography eluting with CH2Cl2:MeOH (95:5) to give (methyl 4-((2-((4-(2-(2-((3r,5r,7r)-adamantan- 1 -yl)acetamido)acetyl)piperazin- 1 - yl)methyl)phenoxy)methyl)benzoate) (517 mg, 56 % yield for 2 steps) as a pale yellow oil. ESI-MS [M+l]=574.1; 1H NMR (600 MHz, CDCb) delta 8.06 (d, 2H, J=8.4), 7.51 (d, 2H, J=7.8), 7.34 (d, IH, J=7.8), 7.24 (t, IH, J=7.8), 6.97 (t, IH, J=7.8), 6.90 (d, IH, J=8.4), 6.48 (br s, IH), 5.15 (s, 2H), 4.03 (d, 2H, J=4.2), 3.93 (s, 3H), 3.65(br s, 4H), 3.40 (t, 2H, J=4.8), 2.50 (br s, 4H), 2.01 (s, 2H), 1.98 (br s, 3H), 1.70-1.62 (m, 12H).

References: [1]Patent: WO2013/22550,2013,A2 .Location in patent: Page/Page column 74.

Yield	Reaction Conditions	Operation in experiment
		General procedure: [0186] To 5-((4-formyl-6-methoxyphen-3-yloxy)methyl)nicotinate (96 mg, 0.32 mmol, 1 eq.) in a mixture of MeOH/THF (1/3, 8.0 mL) is added NaOH (3 N, 1.7 mL, 5.1 mmol, 16 eq.). The mixture is stirred at rt for 2 h, acidified to pH 3, extracted with EtOAc (3 x 20 mL). The combined organic layers are dried over Na2S04 and concentrated to give 5-((4-formyl-6- methoxypyridin-3-yloxy)methyl)nicotinic acid.
		As used herein, Table 1 includes compounds described below or tautomers or pharmaceutically acceptable salts thereof: ...2-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)-5-methoxybenzaldehyde,2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde,2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,2-((4-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,methyl 4((2-formylphenoxy)methyl)benzoate,4-((2-formylphenoxy)methyl)benzoic acid,methyl 3-((2-formylphenoxy)methyl)benzoate,2-bromo-3-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde,...

5
[ 351335-29-0 ]
N₁-(benzyloxycarbonyl)-N₄-[(2-phenylbenzimidazol-5-yl)methyl]piperazine [ No CAS ]
N₁-[[2-[(4-methoxycarbonylphenyl)methoxy]phenyl]methyl]-N₄-[(2-phenylbenzimidazol-5-yl)methyl]piperazine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
79%		General procedure: To a solution of piperazine-Cbz derivative (1 equiv) in MeOH (1.6 mL) palladium on carbon (0.02 g, 0.19 mmol, 1.2eq) was added and mixture was stirred under hydrogen atmosphere overnight at room temperature. Then, palladium catalyst was filtered off. The filtrate was concentrated and dissolved in CH2CI2 (3 mL). To the obtained solution were added aldehyde derivative (lequiv) and sodium triacetoxyborohydride (0.04 g, 0.19 mmol,1.2 equiv). The reaction mixture was stirred at room temperature till the completion (20h), then after addition of water, the solution was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO4 and concentrated. The crude was purified by column chromatography (CH2CI2/MeOH).

References: [1]Patent: WO2018/50771,2018,A1 .Location in patent: Page/Page column 17; 33; 34.

6
[ 351335-29-0 ]
[ 57260-71-6 ]
C₂₅H₃₂N₂O₅ [ No CAS ]